¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"HIV envelope protein gp41"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • C-reactive protein
    C-¹ÝÀÀ´Ü¹éÁú
  • cytotoxic cell protein
    ¼¼Æ÷µ¶¼º¼¼Æ÷´Ü¹éÁú
  • carrier protein
    ¿î¹Ý´Ü¹éÁú
  • catabolite (gene) activator protein
    ºÐÇØ´ë»ç»ê¹°(À¯ÀüÀÚ)Ȱ¼º´Ü¹éÁú
  • catabolite activator protein
    ºÐÇØ´ë»ç»ê¹°È°¼º´Ü¹éÁú
  • denatured protein
    º¯¼º´Ü¹éÁú
  • derived protein
    À¯µµ´Ü¹éÁú
  • different membrane protein
    À¯°ü¸·´Ü¹éÁú
  • extracellular matrix protein
    ¼¼Æ÷¹Ù±ù¹ÙÅÁÁú´Ü¹éÁú, ¼¼Æ÷¿Ü±âÁú´Ü¹éÁú
  • endogenous protein
    ³»ÀδܹéÁú
  • foreign protein
    ÀÌÁ¾´Ü¹éÁú
  • glial fibrillary acidic protein
    ¾Æ±³¼¼Æ÷¼¶À¯»ê¼º´Ü¹éÁú, ±³¼¶À¯»ê¼º´Ü¹éÁú
  • globular protein
    °ø¸ð¾ç´Ü¹éÁú, ±¸»ó´Ü¹éÁú
  • heat-shock protein
    ¿­Ãæ°Ý´Ü¹éÁú
  • heterologous protein
    ÀÌÁ¾´Ü¹éÁú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • denatured protein
    º¯¼º´Ü¹é
  • deposit protein
    ÀúÀå´Ü¹éÁú
  • derived protein
    À¯µµ´Ü¹éÁú
  • different membrane protein
    À¯°ü¸·´Ü¹é
  • endogenous protein
    ³»ÀδܹéÁú
  • extracellular matrix protein
    ¼¼Æ÷¿Ü°£Áú´Ü¹é
  • protein-losing enteropathy
    ´Ü¹é¼Ò½ÇâÀÚº´Áõ
  • foreign protein
    ÀÌÁ¾´Ü¹é
  • protein synthesis factor
    ´Ü¹éÇÕ¼ºÀÎÀÚ
  • globular protein
    ±¸»ó´Ü¹é
  • protein granule
    ´Ü¹éÁú°ú¸³
  • heat-shock protein
    ¿­Ãæ°Ý´Ü¹é
  • heterologous protein
    ÀÌÁ¾´Ü¹é
  • iron binding protein
    ö°áÇմܹéÁú
  • protein bound iodine
    ´Ü¹éÁú°áÇÕ¿ä¿Àµå
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • C-Fos protein
    ¾¾-Æ÷½º´Ü¹é(Ó±ÛÜ)
  • C-reative protein =CRP
    C¹ÝÀÀ¼º ´Ü¹é(Áú).
  • C-reative protein =CRP
    [¸é¿ª] [ÀÓº´]C¹ÝÀÀ¼º ´Ü¹éÁú.
  • DNA-binding protein
    DNA °áÇմܹéÁú
  • G protein
    G ´Ü¹é(Ó±ÛÜ)
  • G-myeloma protein
    ¸é¿ª±Û·ÎºÒ¸° G-°ñ¼öÁ¾´Ü¹éÁú
  • Heat shock protein
    ¿­¼ï´Ü¹éÁú
  • Integral membrane protein
    ÅëÇÕ(÷Öùê) ¸·´Ü¹é(Ø­Ó±ÛÜ)
  • M protein
    M´Ü¹éÁú
  • M protein
    M´Ü¹é.
  • NPN= non protein nitrogen
    ºñ´Ü¹éÁú¼Ò.
  • POMP (principal outer membrane protein)
    ÁÖ¿ä¿Ü¸·´Ü¹éÁú
  • PPD (purified protein derivatives)
    ÇÇÇǵð, Á¤Á¦´Ü¹éÁú·ù(À¯µµÃ¼)
  • PPD(Purified protein derivative) test
    PPD °Ë»ç.
  • Reiters protein
    ¶óÀÌÅÍ ¸Åµ¶Áø´Ü¿ë´Ü¹éÁú
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • activated protein C inhibitor
    Ȱ¼ºÈ­´Ü¹éÁú C ¾ïÁ¦Á¦
  • activated protein C resistance
    Ȱ¼ºÈ­C´Ü¹é³»¼º
  • acute phase protein
    ±Þ¼ºº´±â´Ü¹éÁú
  • acute phase reactive protein
    ±Þ¼º±â ¹ÝÀÀ¼º ´Ü¹é.
  • al protein
    AL ´Ü¹é(¡­Ó±ÛÜ)
  • amyloid precurssor protein
    ¾Æ¹Ð·ÎÀ̵å Àü±¸ ´Ü¹éÁú
  • androgen- binding protein
    ¸¸¼ºÈ£¸£¸ó °áÇմܹé
  • anion exchange protein
    À½À̿ ±³È¯ ´Ü¹é(ÎßüµÓ±ÛÜ)
  • antifreeze protein
    Ç×µ¿°á´Ü¹éÁú(ù÷ÔÐÌ¿ Ó±ÛÜòõ).
  • bacterial cell protein
    ±Õü´Ü¹é(Áú).
  • bactericidal permeability increasing protein(bpip)
    Bactericidal permeability increasing protein
  • bence-jones protein
    º¥½º-Á¸½º ´Ü¹é(¡­Ó±ÛÜ)
  • blood protein
    Ç÷¾×´Ü¹é(¡­Ó±ÛÜ).
  • body protein
    ü´Ü¹é(Áú)(ô÷Ó±ÛÜòõ).
  • c-Jun protein
    ¾¾-ÁØ ´Ü¹é(Ó±ÛÜ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antitumor protein
    Ç×Á¾¾ç ´Ü¹éÁú(ù÷ðþåËÓ±ÛÜòõ)
  • antiviral protein
    Ç×(ù÷) ¹ÙÀÌ·¯½º ´Ü¹éÁú(Ó±ÛÜòõ)
  • A protein
    A ´Ü¹éÁú(Ó±ÛÜòõ)
  • azo-dye protein
    ¾ÆÁ¶»ö¼Ò ´Ü¹éÁú(ßäáÈÓ±ÛÜòõ)
  • Bence-Jones protein
    º¥½º-Á¸½º ´Ü¹éÁú(Ó±ÛÜòõ)
  • binding protein
    °áÇմܹéÁú(Ì¿ùêÓ±ÛÜòõ)
  • binding protein transport system
    °áÇÕ ´Ü¹éÁú ¼ö¼Û(Ì¿ùêÓ±ÛÜòõâÃáê) ½Ã½ºÅÛ
  • biotin carboxyl carrier protein
    ¹ÙÀÌ¿Àƾ Ä«¸£º¹½Ç ¿î¹Ý´Ü¹éÁú(ê¡ÚæÓ±ÛÜòõ)
  • blue copper protein
    ûµ¿ ´Ü¹éÁú(ôìÔÞÓ±ÛÜòõ)
  • blue protein
    û´Ü¹éÁú(ôìÓ±ÛÜòõ)
  • B protein
    B ´Ü¹éÁú(Ó±ÛÜòõ)
  • Ca2+-dependent regulatory protein
    Ca2+-ÀÇÁ¸(ëîðí) Á¶Àý´Ü¹éÁú(ðàï½Ó±ÛÜòõ)
  • calcium-dependent regulatory protein
    Ä®½·ÀÇÁ¸ Á¶Àý´Ü¹éÁú(ëîðíðàï½Ó±ÛÜòõ)
  • cAMP-dependent protein kinase
    cAMPÀÇÁ¸(ëîðí) ´Ü¹éÁú(Ó±ÛÜòõ) Ȱ¼ºÈ­È¿¼Ò(üÀàõûùý£áÈ)
  • carboxyl carrier protein
    Ä«¸£º¹½Ç ¿î¹Ý´Ü¹éÁú(ê¡ÚæÓ±ÛÜòõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HIV human immunodeficiency virus
HIV Ag human immunodeficiency virus antigen
HIV-G human immunodeficiency virus-associated gingivitis
IWB indeterminate [HIV-1] Western blot; index of well being
p24 HIV antigen
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HIV+ HIV seropositive
HIV-1 PR HIV-1 protease
MOS-HIV Medical Outcome Study HIV Health Survey
Env Envelope protein
E2 envelope protein
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • chromatographic protein separation
    Å©·Î¸¶Åä±×·¡Çǹý ´Ü¹é ºÐ¸®
  • D-myeloma protein
    D-°ñ¼öÁ¾ ´Ü¹é
    ¸é¿ª ±Û·ÎºÎ¸°ÀÇ ÇÑ ºÎ·ùÀÎ IgD¸¦ »ý»êÇÏ´Â °ñ¼öÁ¾¿¡¼­ ¸¸µé¾îÁø ´Ü¹éÁú.
  • eosinophil protein X
    È£»ê±¸ ´Ü¹é X
  • estrogen receptor protein
    ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ´Ü¹éÁú
  • hapten-protein conjugate
    ÇÕÅÙ ´Ü¹é °áÇÕ¹°
  • heat-aggregated protein
    ¿­ ÀÀÁý ´Ü¹é
  • hepatic protein
    °£ ´Ü¹é, °£ ´Ü¹éÁú
    °£ÀÇ ´Ü¹éÁú.
  • high protein diet
    °í´Ü¹é ½ÄÀÌ
  • membrane protein
    ¸· ´Ü¹éÁú
  • myotonin-protein kinase
    ¹Ì¿ÀÅä´Ñ-´Ü¹é Ű³ªÁ¦
  • pathologic plasma protein
    º´Àû Ç÷Àå ´Ü¹é
  • penicillin binding protein
    Æä´Ï½Ç¸° °áÇÕ ´Ü¹éÁú
  • perturbation of protein
    ´Ü¹éÁú º¯ÅÂ
  • plasma protein
    Ç÷Àå ´Ü¹é, Ç÷Àå ´Ü¹éÁú
    1. Ç÷Àå¿¡ Á¸ÀçÇÏ´Â ¿©·¯ Á¾·ùÀÇ ´Ü¹éÁú. ¿î¹Ý ´Ü¹éÁú
  • plasma protein binding
    Ç÷Àå ´Ü¹é °áÇÕ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
middle stage HIV disease <disease> This refers to an HIV infection that is characterised by signs and symptoms of HIV that are not life-threatening.
Examples include oral thrush, gingivitis, seborrheic dermatitis, molluscum contangiosum, fevers, fatigue, lymph node swelling, malaise and weight loss. This stage can be a signal for the conversion from asymptomatic HIV disease to HIV disease (moe pronouced symptoms include joint pains). AIDS is diagnosed after HIV disease has started to manifest life-threatening oppotunistic infections (for example pneumocystis, cryptosporidium, toxoplasmosis, etc).
(27 Sep 1997)
primary HIV infection <infectious disease> The flu-like syndrome that oc immediately after a person contracts HIV. This mini infection precedes seroconversion and is characterised fever, sore throat, headache, skin rash and swollen glands.
(06 Mar 1998)
HIV <virology> A type of retrovirus (human immunodeficiency virus) that is responsible for the fatal illness acquired immunodeficiency syndrome. Two strains have been identified.
Type 1: the retrovirus recognised as the agent that induces AIDS.
Type 2: a virus closely related to HIV-1 that also leads to immune suppression. HIV-2 is not as virulent as HIV-1 and is epidemic only in West Africa.
Acronym: HIV
(11 Nov 1997)
HIV-1 The type species of lentivirus and widely recognised as the aetiologic agent of acquired immunodeficiency syndrome (aids). It is characterised by its cytopathic effect and affinity for the t4-lymphocyte.
(12 Dec 1998)
HIV-1 reverse transcriptase <enzyme> HIV-1 enzyme responsible for the synthesis of DNA from genomic RNA of the virus. It is encoded by the pol gene of HIV-1.
Registry number: EC 2.7.7.-
(12 Dec 1998)
HIV-2 An HIV species related to HIV-1 but carrying different antigenic components and with differing nucleic acid composition. It shares serologic reactivity and sequence homology with the simian lentivirus siv and infects only t4-lymphocytes expressing the CD4 phenotypic marker.
(12 Dec 1998)
HIV-2 protease <enzyme> Processes hiv-1pr53(gag) and analogous junction peptides in vitro; less than 60% amino acid identity to hiv-1 protease
Registry number: EC 3.4.23.-
Synonym: hiv2 protease
(26 Jun 1999)
HIV-2 reverse transcriptase <enzyme> Responsible for synthesis of double-stranded DNA from the genomic RNA of the virus; has rnase h and DNA-dependent DNA polymerase activities; was indexed as reverse transcriptase (87-91)
Registry number: EC 2.7.7.-
(26 Jun 1999)
HIV antibodies Antibodies reactive with human immunodeficiency virus (HIV, previously called HTLV-III/lav) antigens of aids. This includes HIV-1 antibodies and HIV-2 antibodies.
(12 Dec 1998)
HIV antigens Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (lav) antigens.
(12 Dec 1998)
HIV encephalopathy <immunology> A frequent cerebral condition in people with AIDS that results in the loss of cognitive capacity, affecting the ability to function in a social or occupational setting.
Its cause has not been determined exactly, but may result from HIV infection of cells in the brain or an inflammatory reaction to such infection.
(09 Oct 1997)
HIV enhancer Cis-acting regulatory sequences in the HIV long terminal repeat (ltr) which play a major role in induction or augmentation of HIV gene expression in response to environmental stimuli such as mitogens, phorbol esters, or other viruses. The HIV enhancer is the binding site for many cellular transcription factors including the nuclear factor nf-kappa b.
(12 Dec 1998)
HIV enteropathy Chronic, well-established diarrhoea (greater than one month in duration) without an identified infectious cause after thorough evaluation, in an HIV-positive individual. It is thought to be due to direct or indirect effects of HIV on the enteric mucosa. HIV enteropathy is a diagnosis of exclusion and can be made only after other forms of diarrhoeal illness have been ruled out.
(12 Dec 1998)
HIV infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru aids-related complex (arc), to acquired immunodeficiency syndrome (aids).
(12 Dec 1998)
HIV integrase <enzyme> Enzyme of the human immunodeficiency virus that is required to integrate viral DNA into cellular DNA in the nucleus of a host cell. HIV integrase is a DNA nucleotidyltransferase encoded by the pol gene.
Registry number: EC 2.7.7.-
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á